Pancreatic Cancer Research

Journal articleValue Health Reg Issues2022

Cost-Effectiveness of Nab-Paclitaxel and Gemcitabine Versus Gemcitabine Monotherapy for Patients with Unresectable Metastatic Pancreatic Cancer in Japan.

Journal
Value Health Reg Issues
Published
17 November 2021
Citations
7
Type
Article
License
cc by-nc-nd

These are the paper’s bibliographic details. A summary of its population, design, endpoints and findings, each tied to a quote, has not been written for this paper yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

abstract cc by-nc-nd

Objectives The purpose of this study was to evaluate the cost-effectiveness of nab-paclitaxel and gemcitabine (GnP) compared with gemcitabine monotherapy (G) for patients with unresectable metastatic pancreatic cancer in Japan from the perspective of healthcare payer. Methods A partitioned survival analysis model was developed to predict costs and quality-adjusted life years (QALYs) for GnP and G. … Excerpt only: this text is the publisher’s. Read it in full at the source.